Overview
ProBNP refers to pro–B-type natriuretic peptide, a precursor molecule released from ventricular myocardium in response to increased pressure or volume overload. When ventricular walls are stretched, proBNP is secreted into the circulation and cleaved into two fragments: BNP, the biologically active hormone, and NT-proBNP, an inactive fragment. Both BNP and NT-proBNP reflect myocardial wall stress and are widely used as cardiac biomarkers.
BNP promotes natriuresis, diuresis, and vasodilation and inhibits the renin–angiotensin–aldosterone system, helping to reduce cardiac workload. NT-proBNP, due to its longer half-life and greater stability, is preferred for chronic evaluation and monitoring of heart failure and treatment response.
Symptoms
Elevated ProBNP or NT-proBNP levels are associated with symptoms of heart failure rather than symptoms caused directly by the peptide itself. Patients commonly present with shortness of breath, especially on exertion or lying down, fatigue, reduced exercise tolerance, ankle or leg swelling, abdominal distension, nocturnal cough, and rapid weight gain due to fluid retention.
In acute decompensated heart failure, symptoms may include severe dyspnea, orthopnea, pulmonary edema, and chest discomfort. Higher levels often correlate with symptom severity and disease progression.
Causes
Increased ProBNP levels are caused by conditions that lead to ventricular wall stress or myocardial strain. Heart failure is the most common cause, including both acute and chronic forms. Other causes include acute coronary syndrome, myocardial infarction, pulmonary hypertension, valvular heart disease, cardiomyopathy, renal failure, sepsis, and volume overload states. Reduced clearance in renal dysfunction also contributes to elevated levels.
Decreased ProBNP levels may be seen in obesity and in patients receiving certain medications such as ACE inhibitors, angiotensin receptor blockers, and diuretics.
Risk Factors
Risk factors for elevated ProBNP include advanced age, hypertension, ischemic heart disease, cardiomyopathy, valvular disorders, chronic kidney disease, diabetes mellitus, and sepsis. Elderly individuals show higher baseline values due to age-related cardiac changes. Patients with reduced left ventricular function or left ventricular hypertrophy are at higher risk of elevated levels. Obesity is associated with relatively lower ProBNP concentrations, which should be considered during interpretation.
Prevention
Prevention focuses on early detection and optimal management of underlying cardiovascular conditions. Good control of blood pressure, diabetes, and ischemic heart disease helps reduce ventricular stress and progression to heart failure. Regular monitoring of ProBNP or NT-proBNP levels assists in assessing disease severity, guiding therapy, and evaluating response to treatment.
Proper blood collection using EDTA plasma, avoidance of hemolyzed samples, and appropriate storage conditions improve test accuracy. Early diagnosis, timely treatment, and regular follow-up help prevent complications and reduce morbidity and mortality associated with heart failure.
